🔗 Share this article

An underground economy for unapproved weight-loss drugs is being driven by TikTok fitness influencers and sellers on messaging platforms, according to recent findings.

Experimental Drug Gaining Traction Online

Retatrutide, which is still in research studies, is being advertised by online personalities for its supposed weight-reducing effects. Viewers are urged to contact these accounts privately for supplier links, while also obtaining promotional offers.

Thriving Commerce on Social Networks

Additionally, a flourishing trade exists on messaging services, where communities with numerous of members share comparison images, injection guides and assertions of next-day UK delivery. Vendors market the substance there before redirecting buyers to WhatsApp for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injection created by American pharmaceutical company Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the successor to Ozempic.

Medical Experts Voice Concerns

However, doctors and pharmacists have cautions that the sale of what remains an unlicensed drug in the UK is worrisome and could lead to individuals administering substances of uncertain source.

Some experts said the demand for the experimental drug could be connected to the increasing cost of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Selling retatrutide on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Several content creators try to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still violate medicines, advertising, and customer regulations, potentially leading to penalties, legal action or prison.

Platform Response and Content Removal

According to the social media company, the service has taken down problematic material and prohibited related hashtags and search suggestions. The company said it was dedicated to maintaining the service safe and allocating resources in strengthening enforcement strategies.

Digital Marketplace Activities

Investigations also discovered communities with up to nine thousand participants marketing retatrutide using Telegram's built-in discovery tool, which functions like a public directory. Entering “retatrutide” immediately displays groups with thousands of users, filled with photos of weight loss, positive testimonials and step-by-step instructions for mixing or injecting at home.

Within minutes of entering one community, a seller posted contact information, where the majority of purchases take place. The vendor provided an instruction manual and guaranteed shipping within two days. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None inquired about body mass, medical conditions or past usage.

Product Details and Pricing

Inside these communities, messages display black plastic parcels with Royal Mail labels, claiming to contain new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at home with purified liquid, or ready-to-use injectors usually sold at £160 for 20 milligrams. When questioned how long a pen should last, sellers give conflicting responses ranging from a few weeks to “depends on your body”.

Service Moderation and Security Measures

A spokesperson for the messaging service said it regularly monitored harmful content on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they can’t verify. Even if the research behind retatrutide is valid, these digital versions may not contain what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service linked the surge in demand to current cost increases for authorized slimming medications such as Mounjaro. “With costs rising, patients are using social media. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the conditions they were made in was clean,” she said.

Her team has previously seen patients injured by self-injection from unverified sources. “We understand the disappointment, but buying from messaging apps or communication platforms is gambling with your health,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Statement

A representative from Eli Lilly stated retatrutide was in phase 3 research studies and had not been reviewed or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they said, adding that any product “falsely representing itself as a Lilly investigational product not yet approved … may expose patients to potentially significant medical dangers”.